Eye Meds Now

 Quick Ophthalmic Drug Search

224 items found
BIMATOPROST (bimatoprost (0.03%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended: 

  • Instill 1 drop into the affected eye(s) once daily in the evening. 
  • Should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect.
  • Reduction of the IOP starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles
  • 7.5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


BLEPH-10 (sulfacetamide sodium (10%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli; Staphylococcus aureus; Streptococcus pneumoniae;  Streptococcus (viridans group); Haemophilus influenzae; Klebsiella species; Enterobacter species.

Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.


Typical Dosing:  

►Conjunctivitis and other superficial ocular infections:

►Conjunctivitis:

  • Instill 1 – 2 drops into the conjunctival sac(s) of the affected eye(s) every 2 – 3 hours initially.
  • Dosages may be tapered by increasing the time interval between doses as the condition responds. 
  • The usual duration of treatment is 7 – 10 days.

►Trachoma:

  • Instill 2 drops into the conjunctival sac(s) of the affected eye(s) every 2 hours.
  • Topical administration must be accompanied by systemic administration.

How Supplied:  
  • 5 mL bottles
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 46° – 77°F (8° – 25°C).
  • Protect from light.
  • Sulfonamide solutions, on long standing, will darken in color and should be discarded.


BLEPHAMIDE (prednisolone acetate (0.2%) – sulfacetamide sodium (10%) ophthalmic ointment; ophthalmic suspension )
Prescription
Topical
Ointment
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against: Neisseria species, Pseudomonas species, and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

This medication has a broad FDA approval for "corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammatory ocular conditions: 

  • Ophthalmic ointment:
    • A small amount, approximately ½ inch ribbon of ointment, should be applied in the conjunctival sac 3 – 4 times daily and once or twice at night
    • Not more than 8 g should be prescribed initially. 
    • The dosing may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.
    • If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.
  • Ophthalmic suspension:
    • Shake well before using.
    • Instill 2 drops into the conjunctival sac every 4 hours during the day and at bedtime. 
    • Not more than 20 milliliters should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in the package insert.
    • Dosage may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.
    • If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic suspension:
    • 5 mL bottles
    • 10 mL bottles

Preservatives:  

phenylmercuric acetate (ophthalmic ointment); benzalkonium chloride (ophthalmic suspension)


Storage:  
  • Ophthalmic ointment:
    • Store at 59° – 77°F (15° – 25°C). 
  • Ophthalmic suspension:
    • Store at 46° – 75°F (8° – 24°C) in an upright position.
    • Protect from light.
    • Protect from freezing. 
    • Sulfonamide solutions darken on prolonged standing and exposure to heat and light.
    • Do not use if solution has darkened.
    • Yellowing does not affect activity.


BOTOX (onabotulinumtoxinA (100 Units; 200 Units) injection)
Prescription
Injectable
Intramuscular
Other Medications
Indications/Usage:

Indicated for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients  12 years of age.


Typical Dosing:  

►Blepharospasm in patients  12 years of age, recommended:

  • For blepharospasm, reconstituted BOTOX is injected using a sterile, 27-30 gauge needle without electromyographic guidance.
  • The initial recommended dose is 1.25 Units – 2.5 Units (0.05 mL – 0.1 mL volume at each site) injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pre-tarsal orbicularis oculi of the lower lid. Avoiding injection near the levator palpebrae superioris may reduce the complication of ptosis. Avoiding medial lower lid injections, and thereby reducing diffusion into the inferior oblique, may reduce the complication of diplopia. Ecchymosis occurs easily in the soft eyelid tissues. This can be prevented by applying pressure at the injection site immediately after the injection.
  • The recommended dilution to achieve 1.25 Units is 100 Units/8 mL; for 2.5 Units it is 100 Units/4 mL (See Dilution Table in package insert).
  • In general, the initial effect of the injections is seen within 3 days and reaches a peak at 1 to 2 weeks post-treatment. Each treatment lasts approximately 3 months, following which the procedure can be repeated. At repeat treatment sessions, the dose may be increased up to two-fold if the response from the initial treatment is considered insufficient, usually defined as an effect that does not last longer than 2 months. However, there appears to be little benefit obtainable from injecting more than 5 Units per site. Some tolerance may be found when BOTOX is used in treating blepharospasm if treatments are given any more frequently than every 3 months, and is rare to have the effect be permanent.
  • The cumulative dose of BOTOX treatment for blepharospasm in a 30-day period should not exceed 200 Units.

►Strabismus in patients  12 years of age, recommended:

  • BOTOX is intended for injection into extraocular muscles utilizing the electrical activity recorded from the tip of the injection needle as a guide to placement within the target muscle. Injection without surgical exposure or electromyographic guidance should not be attempted. Physicians should be familiar with electromyographic technique.
  • To prepare the eye for BOTOX injection, it is recommended that several drops of a local anesthetic and an ocular decongestant be given several minutes prior to injection.
  • Note: The volume of BOTOX injected for treatment of strabismus should be between 0.05 – 0.15 mL per muscle.
  • The initial listed doses of the reconstituted BOTOX [See Dosage and Administration (2.2) in package insert] typically create paralysis of the injected muscles beginning one to two days after injection and increasing in intensity during the first week. The paralysis lasts for 2 – 6 weeks and gradually resolves over a similar time period. Overcorrections lasting over 6 months have been rare. About ½ of patients will require subsequent doses because of inadequate paralytic response of the muscle to the initial dose, or because of mechanical factors such as large deviations or restrictions, or because of the lack of binocular motor fusion to stabilize the alignment:
    • Initial doses in Units. Use the lower listed doses for treatment of small deviations. Use the larger doses only for large deviations:
      • For vertical muscles and for horizontal strabismus of less than 20 prism diopters: 1.25 Units – 2.5 Units in any one muscle.
      • For horizontal strabismus of 20 prism diopters to 50 prism diopters: 2.5 Units – 5 Units in any one muscle.
      • For persistent VI nerve palsy of 1 month or longer duration: 1.25 Units – 2.5 Units in the medial rectus muscle.
    • Subsequent doses for residual or recurrent strabismus:
      • It is recommended that patients be re-examined 7 – 14 days after each injection to assess the effect of that dose.
      • Patients experiencing adequate paralysis of the target muscle that require subsequent injections should receive a dose comparable to the initial dose.
      • Subsequent doses for patients experiencing incomplete paralysis of the target muscle may be increased up to two-fold compared to the previously administered dose.
      • Subsequent injections should not be administered until the effects of the previous dose have dissipated as evidenced by substantial function in the injected and adjacent muscles.
      • The maximum recommended dose as a single injection for any one muscle is 25 Units.
  • The recommended dilution to achieve 1.25 Units is 100 Units/8 mL; for 2.5 Units it is 100 Units/4 mL (See Dilution Table in package insert).
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 100 Unit single-use vials
  • 200 Unit single-use vials

Preservatives:  

None listed in package insert.


Storage:  
  • Unopened vials of BOTOX should be stored in a refrigerator 36° – 46°F (2° – 8°C) for up to 36 months.
  • Do not use after the expiration date on the vial.
  • Reconstituted BOTOX may be stored in a refrigerator, 36° – 46°F (2° – 8°C), for up to 24 hours until time of use [See Dosage and Administration (2.2) in package insert].


Assistance: Payment Assistance

BRIMONIDINE (brimonidine tartrate (0.15%; 0.2%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Alpha Agonists
Indications/Usage:

Indicated for lowering elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended: 

  • Instill 1 drop in the affected eye(s) 3 times daily, approximately 8 hours apart.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.

How Supplied:  
  • 0.15% ophthalmic solution:
    • 5 mL bottles
    • 10 mL bottles
    • 15 mL bottles
  • 0.2% ophthalmic solution:
    • 5 mL bottles
    • 10 mL bottles
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15° – 25°C). 


BROMFENAC (bromfenac (0.09%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
NSAIDS
Indications/Usage:

Indicated for the treatment of post-operative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.


Typical Dosing:  

►Post-operative inflammation and ocular pain in patients who have undergone cataract surgery, recommended: 

  • Instill 1 drop into the affected eye(s) once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days of the post-operative period.
  • Use with other topical ophthalmic medications: 
    • May be administered in conjunction with other topical ophthalmic medications such as alpha agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
    • Drops should be administered at least 5 minutes apart.

How Supplied:  
  • 1.7 mL bottles

Note: Bromfenac is also available in 0.07% and 0.075% ophthalmic solutions. See Prolensa (0.07%) and/or BromSite (0.075%) cards for further information.


Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


BROMSITE (bromfenac (0.075%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
NSAIDS
Indications/Usage:

Indicated for the treatment of post-operative inflammation and the prevention of ocular pain in patients undergoing cataract surgery.


Typical Dosing:  

►Post-operative inflammation and ocular pain in patients undergoing cataract surgery, recommended: 

  • Instill 1 drop into the affected eye(s) 2 times daily (morning and evening) beginning 1 day prior to surgery, the day of surgery and 14 days post-surgery.
  • Use with other topical ophthalmic medications: 
    • May be administered in conjunction with other topical ophthalmic medications such as alpha agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
    • Should be administered at least 5 minutes after instillation of other topical medications.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Discard after treatment completion.


Assistance: Payment Assistance

CARTEOLOL (carteolol hydrochloride (1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Has been shown to be effective in lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other IOP-lowering medications.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension, usual dose:

  • Usual dosage is to instill 1 drop into the affected eye(s) twice a day.
  • If the patient’s IOP is not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles
  • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect from light.


CEFDINIR (cefdinir (300 mg) capsules; (125 mg/5 mL; 250 mg/5 mL) oral suspension)
Prescription
Oral
Capsules
Oral Suspension
Antibiotics
Indications/Usage:

Indicated for the treatment of: skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocyctitis caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes.

This medication has a broad FDA approval for mild to moderate "uncomplicated skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "uncomplicated skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocystitis:

  • Adults and adolescents ≥ 13 years:
    • Take 300 mg every 12 hours for 10 days.
    • May be taken without regard to meals.
  • Children 6 months – 12 years:
    • 14 mg/kg every 24 hours OR 7 mg/kg every 12 hours for 10 days.
    • Pediatric patients who weigh ≥ 43 kg should receive the maximum daily dose of 600 mg.
  • Patients with renal insufficiency:
    • CrCl < 30 mL/min: Take 300 mg once daily.
  • Patients on hemodialysis:
    • Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.
  • Consult package insert for additional information.

How Supplied:  
  • Capsules:
    • 300 mg capsules
  • Oral suspension:
    • 125 mg/5 mL suspension (60 mL, 100 mL bottles)
    • 250 mg/5 mL suspension (60 mL, 100 mL bottles)

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Capsules:
    • Store at 68° – 77°F (20° – 25°C).
  • Oral suspension:
    • SHAKE ORAL SUSPENSION WELL BEFORE EACH ADMINISTRATION.
    • Store at 68° – 77°F (20° – 25°C).
    • Discard unused suspension after 10 days.


CEFPROZIL (cefprozil (125 mg/5 mL; 250 mg/5 mL) oral suspension (250 mg; 500 mg) tablets)
Prescription
Oral
Oral Suspension
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of: skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocyctitis.

This medication has a broad FDA approval for mild to moderate "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocystitis:

  • Adults (13 years and older):
    • 250 mg every 12 hours, or 500 mg every 24 hours, or 500 mg every 12 hours for 10 days.
  • Children 2 years – 12 years:
    • 20 mg/kg/day every 24 hours for 10 days.
    • Do not exceed recommended adult doses.
  • Patients with impaired renal function:
    • CrCl 30 – 120 mL/min: Use standard dosage and standard interval.
    • CrCl 0 – 29 mL/min: Use 50% of standard dosage. Use standard interval.
    • Cefprozil is in part removed by hemodialysis; therefore, cefprozil should be administered after the completion of hemodialysis.
  • Patients with hepatic impairment:
    • No dosage adjustment is necessary for patients with impaired hepatic function.
  • Consult package insert for additional information.

How Supplied:  
  • Oral suspension:
    • 125 mg/5 mL suspension (50 mL, 75 mL, 100 mL bottles)
    • 250 mg/5 mL suspension (50 mL, 75 mL, 100 mL bottles)
  • Tablets:
    • 250 mg tablets
    • 500 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Oral suspension:
    • SHAKE ORAL SUSPENSION WELL BEFORE USING.
    • Store in a refrigerator.
    • Discard unused portion after 14 days.
  • Tablets:
    • Store at 68° – 77°F (20° – 25°C).


CEFTRIAXONE (cefriaxone (250 mg; 500 mg; 1 g; 2 g) injection)
Prescription
Injectable
Intramuscular
Antibiotics
Indications/Usage:

Indicated for the treatment of the following infections when caused by susceptible organisms: gonococcal conjunctivitis or keratoconjunctivitis.

Consult package insert for additional information.

This medication has FDA approval for "infections caused by Neisseria gonorrhoeae." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "infections caused by Neisseria gonorrhoeae." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Conjunctivitis, gonococcal or keratoconjunctivitis, gonococcal:

  • Adults:
    • Inject 1 g IM as a single dose.
    • Give in combination with 1 g azithromycin taken by mouth as a single dose.
  • Additional information for Intramuscular Administration is in Notes below.
Dosing based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Single use vials for reconstitution:
    • 250 mg vials
    • 500 mg vials
    • 1 g vials
    • 2 g vials

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Storage powder at 68° – 77°F (20° – 25°C).
  • Protect from light.
  • Consult package insert for information on storage after reconstitution.


CEPHALEXIN (cephalexin (250 mg; 500 mg; 750 mg) capsules; (125 mg/5 mL; 250 mg/5 mL) oral suspension; (250 mg; 500 mg) tablets)
Prescription
Oral
Capsules
Oral Suspension
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of skin and skin structure infections, such as presptal cellulitis, internal hordeolum, dacryocystitis, caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes.

This medication has a broad FDA approval for "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Skin and skin structure infections:

  • Adults and patients  15 years of age: 
    • The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 – 14 days. For more severe infections larger doses may be needed, up to 4 grams daily in 2 – 4 equally divided doses.
  • Children (1 year of age):
    • Recommended total daily dose is 25 – 50 mg/kg given in equally divided doses for 7 – 14 days. In the treatment of β-hemolytic streptococcal infections, duration of at least 10 days is recommended. In severe infections, a total daily dose of 50 – 100 mg/kg may be administered in equally divided doses.
  • Dosage adjustment is required in patients with severe and end stage renal disease (ESRD) defined as CrCl < 30 mL/min. 
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • Capsules:
    • 250 mg capsules
    • 500 mg capsules
    • 750 mg capsules
  • Oral suspension:
    • 125 mg/5 mL oral suspension (100 mL, 200 mL bottles)
    • 250 mg/5 mL oral suspension (100 mL, 200 mL bottles)
  • Tablets:
    • 250 mg tablets
    • 500 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 77ºF (25ºC).
  • Excursions permitted to 59º –  86ºF (15º – 30ºC).
  • Dispense in a tight, light-resistant container.


CETIRIZINE (cetirizine hydrochloride (10 mg) capsules, liquid filled; (10 mg) tablets, orally disintegrating; (10 mg) tablets)
Over the Counter
Oral
Capsules
Oral Disintegrating Tablets
Oral Solution
Tablets
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

Runny nose; sneezing; itchy, watery eyes; itching of the nose or throat:

  • Adults and children 6 years of age:
    • One 10 mg capsule or tablet once a day.
    • A 5 mg product may be appropriate for less severe symptoms.
    • Do not take more than one 10 mg capsule or tablet in 24 hours.
    • Orally disintegrating tablet melts in mouth. Can be taken with or without water.
  • Adults   65 years of age:
    • Ask a doctor.
  • Children < 6 years of age: 
    • Ask a doctor.
  • Individuals with liver or kidney disease:
    • Ask a doctor.

How Supplied:  
  • Capsules:
    • 10 mg capsules
  • Tablets, orally disintegrating:
    • 10 mg orally disintegrating tablets
  • Tablets:
    • 5 mg tablets
    • 10 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Avoid high humidity and excessive heat above 104°F (40°C).
  • Protect from light.


CETIRIZINE CHILDREN'S (cetirizine hydrochloride (5 mg/5 mL) oral solution; (10 mg) tablets, orally disintegrating)
Over the Counter
Oral
Oral Disintegrating Tablets
Oral Solution
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

Runny nose; sneezing; itchy, watery eyes; itching of the nose or throat:

  • Tablets, orally disintegrating:
    • Adults and children 6 years of age:
      • One 10 mg capsule or tablet once a day.
      • A 5 mg product may be appropriate for less severe symptoms.
      • Do not take more than one 10 mg capsule or tablet in 24 hours.
    • Adults   65 years of age:
      • Ask a doctor.
    • Children < 6 years of age: 
      • Ask a doctor.
    • Individuals with liver or kidney disease:
      • Ask a doctor.
    • Orally disintegrating tablet melts in mouth. Can be taken with or without water.
  • Oral solution:
    • Adults and children 6 years of age:
      • 5 mL or 10 mL once a day depending upon severity of symptoms.
      • Do not take more than 10 mL in 24 hours.
    • Adults  65 years of age:
      • 5 mL once a day.
      • Do not take more than 5 mL in 24 hours.
    • Children 2 to < 6 years of age: 
      • 2.5 mL once daily. If needed, dose can be increased to a maximum of 5 mL once daily or 2.5 mL every 12 hours.
      • Do not give more than 5 mL in 24 hours.
    • Children < 2 years of age: 
      • Ask a doctor.
    • Individuals with liver or kidney disease:
      • Ask a doctor.
    • Use only with enclosed dosing cup.

How Supplied:  
  • Oral solution:
    • 5 mg/5 mL oral solution
  • Tablets, orally disintegrating:
    • 10 mg orally disintegrating tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Avoid high humidity and excessive heat above 104°F (40°C).
  • Protect from light.


CILOXAN (ciprofloxacin hydrochloride (0.3%) ophthalmic solution; ophthalmic ointment)
Prescription
Topical
Ointment
Ophthalmic Solution
Antibiotics
Indications/Usage:

Ophthalmic ointment is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following microorganisms: Gram-Positive: Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus Viridans Group. Gram-Negative: Haemophilus influenzae.

Ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Corneal ulcers: Pseudomonas aeruginosa; Serratia marcescens*; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus Viridans Group*. Conjunctivitis: Haemophilus influenzae; Staphylococcus aureus; Staphylococcus epidermis; Streptococcus pneumoniae.

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

Bacterial conjunctivitis, recommended:

  • Ophthalmic ointment: 
    • Apply a ½ inch ribbon into the conjunctival sac 3 times a day on the first 2 days, then apply a ½ inch ribbon 2 times a day for the next 5 days. 
  • Ophthalmic solution:
    • Instill 1 – 2 drops into the conjunctival sac(s) every 2 hours while awake for 2 days, and 1 – 2 drops every 4 hours while awake for the next 5 days.

Corneal ulcers, recommended:

  • Ophthalmic solution:
    • Instill 2 drops into the affected eye(s) every 15 minutes for the first 6 hours, and then 2 drops into the affected eye(s) every 30 minutes for the remainder of the first day.
    • On the 2nd day, instill 2 drops into the affected eye(s) hourly.
    • On the 3rd – 14th day, instill 2 drops into the affected eye(s) every 4 hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.
  • Additional information for pediatric use is in Notes below: 

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic solution:
    • 2.5 mL bottles (generic only)
    • 5 mL bottles
    • 10 mL bottles (generic only)

Preservatives:  

benzalkonium chloride (ophthalmic solution); none listed in package insert (ophthalmic ointment).


Storage:  
  • Store at 36° – 77°F (2° – 25°C).
  • Protect ophthalmic solution from light.


CIPROFLOXACIN (ciprofloxacin hydrochloride (0.3%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Corneal ulcers: Pseudomonas aeruginosa; Serratia marcescens*; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus Viridans Group*. Conjunctivitis: Haemophilus influenzae; Staphylococcus aureus; Staphylococcus epidermis; Streptococcus pneumoniae.

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

►Bacterial conjunctivitis, recommended: 

  • Instill 1 – 2 drops into the conjunctival sac(s) every 2 hours while awake for 2 days, and 1 – 2 drops every 4 hours while awake for the next 5 days.

Corneal ulcers, recommended: 

  •  Instill 2 drops into the affected eye(s) every 15 minutes for the first 6 hours, and then 2 drops into the affected eye(s) every 30 minutes for the remainder of the first day.
  • On the 2nd day, instill 2 drops into the affected eye(s) hourly.
  • On the 3rd – 14th day, instill 2 drops into the affected eye(s) every 4 hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occured.
  • Additional information for pediatric use is in Notes below: 

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36° – 77°F (2° – 25°C).
  • Protect from light.


CLARINEX (desloratadine (5 mg) tablets, film coated; (2.5 mg; 5 mg) tablets, orally disintegrating; (0.5 mg/mL) oral solution)
Prescription
Oral
Oral Disintegrating Tablets
Oral Solution
Tablets
Antihistamines
Indications/Usage:

Indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older and for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older.


Typical Dosing:  

►Nasal and non-nasal symptoms of seasonal or perennial allergic rhinitis:

  • Tablets or tablets, orally disintegrating:
    • Adults and adolescents 12 years of age, recommended:
      • One 5 mg tablet once daily.
    • Adults with hepatic or renal impairment:
      • A starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.
    • Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [See Clinical Pharmacology (12.3) in package insert].
  • Oral solution:
    • Adults and adolescents 12 years of age, recommended:
      • 10 mL (5 mg) once daily.
    • Children 6 – 11 years of age, recommended:
      • 5 mL (2.5 mg) once daily.
    • Children 12 months – 5 years of age, recommended:
      • 2.5 mL (1.25 mg) once daily.
    • Children 6 – 11 months of age, recommended:
      • 2 mL (1 mg) once daily.

How Supplied:  
  • Tablets:
    • 5 mg tablets
  • Tablets, orally disintegrating:
    • 2.5 mg tablets (generic only)
    • 5 mg tablets (generic only)
  • Oral solution:
    • 0.5 mg/mL solution

Preservatives:  

None listed in package insert (tablets); sodium benzoate, disodium edetate (oral solution)


Storage:  
  • Tablets:
    • Store at 77°F (25°C); excursions permitted to 59° – 86°F (15° – 30°C).
    • Heat sensitive; avoid exposure at or above 86°F (30°C).
  • Oral solution:
    • Store at 77°F (25°C); excursions permitted to 59° – 86°F (15° – 30°C).
    • Protect from light.


CLARITIN (loratadine (10 mg) capsules; (10 mg) tablets; (10 mg) tablets, orally disintegrating)
Over the Counter
Oral
Capsules
Oral Disintegrating Tablets
Tablets
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

Runny nose; sneezing; itchy, watery eyes; itching of the nose or throat:

  • Adults and children 6 years of age:
    • Take 1 tablet or capsule daily.
    • Do not take more than 1 tablet or capsule in 24 hours
  • Children < 6 years of age:
    • Ask a doctor.
  • Individuals who have liver or kidney disease:
    • Ask a doctor.

How Supplied:  
  • Capsules:
    • 10 mg capsules
  • Tablets:
    • 10 mg tablets
  • Tablets, orally disintegrating
    • 10 mg tablets, orally disintegrating

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Protect from excessive moisture.
  • Protect from freezing.
  • Use orally disintegrating tablets immediately after opening individual blister.


CLARITIN CHILDREN'S (loratadine (5 mg) chewables; (5 mg/5 mL) oral solution)
Over the Counter
Oral
Chewable Tablets
Oral Solution
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

Runny nose; sneezing; itchy, watery eyes; itching of the nose or throat:

  • Chewable tablets:
    • Adults and children 6 years of age:
      • Chew 2 tablets daily.
      • Do not take more than 2 tablets in 24 hours.
    • Children 2 to < 6 years of age:
      • Chew 1 tablet daily.
      • Do not take more than 1 tablet in 24 hours.
    • Children < 2 years of age:
      • Ask a doctor.
    • Individuals who have liver or kidney disease:
      • Ask a doctor.
  • Oral solution:
    • Adults and children 6 years of age:
      • 10 mL (10 mg) daily.
      • Do not take more than 10 mL (10 mg) in 24 hours.
    • Children 2 to 6 years of age:
      • 5 mL (5 mg) daily.
      • Do not take more than 5 mL (5 mg) in 24 hours.
    • Children < 2 years of age:
      • Ask a doctor.
    • Individuals who have liver or kidney disease:
      • Ask a doctor.

How Supplied:  
  • Chewables:
    • 5 mg chewables
  • Oral solution:
    • 5 mg/5 mL solution

Preservatives:  

None listed in package insert (chewables); disodium edetate, sodium benzoate (oral solution)


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Protect from excessive moisture.
  • Protect from freezing.


COMBIGAN (brimonidine tartrate (0.2%) – timolol maleate (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Combinations
Indications/Usage:

Indicated for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

The IOP-lowering of COMBIGAN® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed 3 times per day.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP, recommended: 

  • Instill 1 drop into the affected eye(s) 2 times daily, approximately 12 hours apart. 
  • If more than 1 topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect from light.


Assistance: Payment Assistance

224 items found